UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 133

Sortiert nach

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2021-04, Vol.13 (1), p.80-80, Article 80

2021

Link zum Volltext

Verfügbarkeit prüfen

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Alzheimer's research & therapy, 2022-12, Vol.14 (1), p.191-191, Article 191

2022

Link zum Volltext

Verfügbarkeit prüfen

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Alzheimer's & dementia, 2023-04, Vol.19 (4), p.1227-1233

2023

Link zum Volltext

Verfügbarkeit prüfen

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Nature reviews. Drug discovery, 2005-02, Vol.4 (2), p.131-144

2005

Link zum Volltext

Verfügbarkeit prüfen

Lecanemab in Early Alzheimer’s Disease

The New England journal of medicine, 2023-01, Vol.388 (1), p.9-21

2023

Link zum Volltext

Verfügbarkeit prüfen

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

Alzheimer's research & therapy, 2022-12, Vol.14 (1), p.182-182, Article 182

2022

Link zum Volltext

Verfügbarkeit prüfen

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2023-01, Vol.9 (1), p.e12377-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Link zum Volltext

Verfügbarkeit prüfen

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2022-05, Vol.14 (1), p.70-70, Article 70

2022

Link zum Volltext

Verfügbarkeit prüfen

Anxiolytic- and Antidepressant-like Profiles of the Galanin-3 Receptor ($Gal_3$) Antagonists SNAP 37889 and SNAP 398299

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (48), p.17489-17494

2005

Link zum Volltext

Verfügbarkeit prüfen

Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses

PloS one, 2011-08, Vol.6 (8), p.e24269-e24269

2011

Link zum Volltext

Verfügbarkeit prüfen

The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

The Journal of pharmacology and experimental therapeutics, 2002-12, Vol.303 (3), p.919

2002

Link zum Volltext

Verfügbarkeit prüfen

The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate

The Journal of neuroscience, 2002-10, Vol.22 (20), p.9134-9141

2002

Link zum Volltext

Verfügbarkeit prüfen

A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists

Annals of the New York Academy of Sciences, 2003-11, Vol.1003 (1), p.309-317

2003

Link zum Volltext

Verfügbarkeit prüfen

Feeding induced by blockade of AMPA and kainate receptors within the ventral striatum: a microinfusion mapping study

Behavioural brain research, 1997-12, Vol.89 (1), p.107-113

1997

Link zum Volltext

Verfügbarkeit prüfen

The mGlu2/3 receptor agonist, LY354740, blocks immobilization‐induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex

Journal of neurochemistry, 2004-01, Vol.88 (1), p.194-202

2004

Link zum Volltext

Verfügbarkeit prüfen

Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell

Behavioural brain research, 1998-06, Vol.93 (1), p.43-50

1998

Link zum Volltext

Verfügbarkeit prüfen

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

JAMA network open, 2023-04, Vol.6 (4), p.e237230-e237230

2023

Link zum Volltext

Verfügbarkeit prüfen

Repeated Cocaine Administration Attenuates Group I Metabotropic Glutamate Receptor-Mediated Glutamate Release and Behavioral Activation: A Potential Role for Homer

The Journal of neuroscience, 2001-11, Vol.21 (22), p.9043-9052

2001

Link zum Volltext

Verfügbarkeit prüfen

CONSIDERATION FOR “EARLY ALZHEIMER'S DISEASE (AD)” TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401-G000-201 TRIAL

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P778-P778

2014

Link zum Volltext

Verfügbarkeit prüfen

Regulation of locomotor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area

The Journal of pharmacology and experimental therapeutics, 2000-01, Vol.292 (1), p.406

2000

Link zum Volltext

Verfügbarkeit prüfen

The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice

European journal of pharmacology, 2009-01, Vol.602 (1), p.66-72

2009

Link zum Volltext

Verfügbarkeit prüfen

Modeled Impact of APOE4 Genotype on ARIA‐E Incidence in Patients Treated With Lecanemab

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Derivation and evaluation of signatures using plasma β‐amyloid and pTau‐181 for brain amyloid‐β detection

Alzheimer's & dementia, 2022-12, Vol.18 (S5), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(131)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(73)
Humans
(42)
Male
(33)
Animals
(28)
Neurosciences & Neurology
(23)
Female
(18)
Neurosciences
(16)
Clinical Neurology
(14)
Rats
(13)
Rats, Sprague-Dawley
(13)
Middle Aged
(12)
Virology
(11)
Adult
(9)
Aged
(9)
Biochemistry & Molecular Biology
(9)
Biological And Medical Sciences
(9)
Neurology
(9)
Excitatory Amino Acid Antagonists - Pharmacology
(8)
Mice
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Lecanemab in Early Alzheimer’s Disease

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Anxiolytic- and Antidepressant-like Profiles of the Galanin-3 Receptor ($Gal_3$) Antagonists SNAP 37889 and SNAP 398299

Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses

The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate

A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists

Feeding induced by blockade of AMPA and kainate receptors within the ventral striatum: a microinfusion mapping study

The mGlu2/3 receptor agonist, LY354740, blocks immobilization‐induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex

Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

Repeated Cocaine Administration Attenuates Group I Metabotropic Glutamate Receptor-Mediated Glutamate Release and Behavioral Activation: A Potential Role for Homer

CONSIDERATION FOR “EARLY ALZHEIMER'S DISEASE (AD)” TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401-G000-201 TRIAL

Regulation of locomotor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area

The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice

Modeled Impact of APOE4 Genotype on ARIA‐E Incidence in Patients Treated With Lecanemab

Derivation and evaluation of signatures using plasma β‐amyloid and pTau‐181 for brain amyloid‐β detection

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects

Suchergebnisse filtern